ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for Cancer Research

Executive Summary: ABT-888 (Veliparib) is a highly selective inhibitor of PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymes, essential for DNA single-strand break repair (APExBIO). It potently sensitizes tumor cells to cytotoxic chemotherapy and radiation by impairing DNA repair mechanisms (Pettenger-Willey et al., 2026). ABT-888 is particularly effective in models with microsatellite instability (MSI) or homologous recombination deficiency (HRD), such as those with MRE11 or RAD50 mutations. The compound exhibits strong synergy with SN38 and oxaliplatin in colorectal cancer cell lines. For optimal experimental reproducibility, ABT-888 is used in DMSO-based stock solutions, stored at -20°C and protected from light (see methods guide).

Biological Rationale

DNA repair is a fundamental process which maintains genomic stability. Poly (ADP-ribose) polymerases (PARP1/2) detect and facilitate repair of single-strand DNA breaks via the PARP-mediated DNA repair pathway. Inhibition of PARP activity in tumors with defective homologous recombination repair (e.g., BRCA1/2, MRE11, RAD50 mutations) induces synthetic lethality, leading to cell death. This makes PARP inhibitors, including ABT-888, valuable for targeting cancers with DNA repair deficiencies (Pettenger-Willey et al., 2026).

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) is a competitive inhibitor of the NAD⁺ binding site of PARP1 and PARP2. It blocks poly-ADP-ribosylation of target proteins, preventing recruitment of DNA repair complexes to sites of single-strand DNA breaks. This action leads to accumulation of DNA damage, especially in cells lacking efficient homologous recombination. The molecular weight is 244.3 g/mol, and the chemical formula is C₁₃H₁₆N₄O (APExBIO). The compound is insoluble in water but dissolves in DMSO (≥6.11 mg/mL) and ethanol (≥10.6 mg/mL with ultrasonication). Stock solutions above 10 mM in DMSO are recommended for experimental assays (see detailed workflow).

Evidence & Benchmarks

• ABT-888 (Veliparib) demonstrates Ki values of 5.2 nM (PARP1) and 2.9 nM (PARP2), confirming high potency and selectivity (APExBIO).
• In HCT-116 and HT-29 colon cancer cell lines, ABT-888 synergizes with SN38 and oxaliplatin, reducing PARP activity and enhancing cytotoxicity (see SN38 synergy guide).
• In vivo, oral ABT-888 at 12.5 mg/kg BID in female nude athymic mice bearing HCT116 xenografts significantly delays tumor growth when combined with radiation and CPT-11 chemotherapy (see Table 2, DOI).
• PARP inhibition by ABT-888 is most effective in tumor models with microsatellite instability or DNA repair gene mutations (e.g., MRE11, RAD50) (see translational update).
• Genome-wide CRISPR screens confirm PARP inhibitors have limited impact on calicheamicin-induced cytotoxicity in acute leukemia, highlighting pathway specificity (DOI).

Applications, Limits & Misconceptions

ABT-888 (Veliparib) is primarily used in preclinical research for:

• Sensitizing tumor cells to chemotherapy (e.g., SN38, oxaliplatin) and radiation.
• Modeling DNA damage response and therapeutic resistance in colorectal and glioblastoma research.
• Studying synthetic lethality in homologous recombination-deficient (HRD) and microsatellite instability (MSI) tumor models.
• Assessing PARP-mediated DNA repair pathways using colon cancer cell lines (HCT-116, HT-29) and xenograft models.

Common Pitfalls or Misconceptions

• ABT-888 is not effective in all tumor types; activity depends on DNA repair status (e.g., HRD or MSI tumors show most benefit).
• It does not significantly enhance cytotoxicity of calicheamicin-based antibody-drug conjugates in acute leukemia models (DOI).
• The compound is not water-soluble; improper dissolution may lead to inaccurate dosing.
• ABT-888 is for scientific research use only, not for diagnostic or clinical therapy.
• Long-term storage of solutions is not recommended; compound stability may be compromised.

Workflow Integration & Parameters

For laboratory use, ABT-888 (Veliparib, A3002) is typically prepared as a ≥10 mM stock in DMSO, with warming and ultrasonication to aid dissolution (see Q&A guide). Working concentrations in cell culture range from 0.1 to 10 μM, depending on cell type and desired PARP inhibition. Solutions and solid compound are stored at -20°C, protected from light. For in vivo studies, oral dosing at 12.5 mg/kg BID has shown efficacy in mouse xenograft models. APExBIO, as the original manufacturer, provides validated protocols and batch-specific data sheets for reproducibility.

For further optimization, see the methods overview (atomic workflow guide) and scenario-driven troubleshooting (scenario FAQ). This article extends prior resources by clarifying effective concentration ranges, storage caveats, and the molecular rationale for model selection.

Conclusion & Outlook

ABT-888 (Veliparib) is a well-characterized PARP1 and PARP2 inhibitor with proven utility in DNA damage response and chemotherapy sensitization research. Its greatest impact is observed in models of homologous recombination deficiency and microsatellite instability, where synthetic lethality is exploited for tumor cell killing. While not universally effective across all DNA damage pathway contexts, ABT-888 remains a critical tool for dissecting PARP-mediated DNA repair and optimizing combination therapy protocols in preclinical settings. For comprehensive product specifications or to source the compound, visit the official ABT-888 (Veliparib) product page from APExBIO.